REG-Genmab Announces Financial Results for the First Quarter of 2026
Genmab reported Q1 2026 revenue of $896 million, up 25% year-over-year, fueled by higher royalties from DARZALEX and Kesimpta collaborations as well as EPKINLY net product sales. The FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for EPKINLY patients, a significant commercial catalyst.
Key figures
- Revenue
- 896000000
- Guidance
- Maintained 2026 financial guidance published February 17, 2026
- Revenue Yoy
- 25%
- Opex ex charges
- 606000000
- Royalty revenue
- 742000000
- Operating profit
- 180000000
- Acquisition charges
- 45000000
- Operating profit ex items
- 237000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.